(Q37829690)

24 August 2017

1 reference

title

Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications (English)

1 reference

24 August 2017

author

Athanasios Dimopoulos

object named as

Meletios A Dimopoulos

series ordinal

2

0 references

author name string

Evangelos Terpos

series ordinal

1

1 reference

24 August 2017

publication date

18 January 2011

1 reference

Cancer Immunology, Immunotherapy

24 August 2017

published in

1 reference

24 August 2017

volume

60

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

305-317

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-011-0974-x

24 August 2017

exact match

0 references

cites work

Osteoimmunology: interactions of the bone and immune system

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Osteoimmunology--the hidden immune regulation of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Strength of TRAF6 signalling determines osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Regulation of osteoclast differentiation and function by the CaMK-CREB pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Fos/AP-1 proteins in bone and the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Increased serum concentrations of Soluble CD40 Ligand as a prognostic marker in patients with Acute Coronary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Shared gene expression profiles in developing heart valves and osteoblast progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Autoamplification of NFATc1 expression determines its essential role in bone homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Molecular mechanisms of inflammatory bone damage: emerging targets for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

The cell biology of bone metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Osteoimmunology: interplay between the immune system and bone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Osteoimmunology: a view from the bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Mechanisms of T regulatory cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

NF-κB as a central regulator of macrophage function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

21 January 2018

Cancer micrometastases

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Micrometastases in non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

RANK ligand as a therapeutic target for bone metastases and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Review of 1027 patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Regulation of cancer cell migration and bone metastasis by RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Osteoprotegerin and rank ligand expression in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

RANK ligand and osteoprotegerin in myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

RANK ligand is a prerequisite for cancer-associated osteolytic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Induction of proliferation and augmented cytotoxicity of gammadelta T lymphocytes by bisphosphonate clodronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Recent advances in understanding the mechanism of action of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Activation of γδ T cells by bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Myeloma bone disease: pathophysiology and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Zoledronate Stimulates γδ T Cells in Prostate Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Bisphosphonates induce apoptosis in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

RANKL inhibition for the management of patients with benign metabolic bone disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0974-X

10.1007/S00262-011-0974-X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference